Short answer
Arcturus Therapeutics Holdings Inc. (ARCT) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Forward-looking disclosure tied to ARCT-032, ARCT-810, and CSL Seqirus-partnered COVID-19 and flu programs.
Arcturus Therapeutics Holdings Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Forward-looking disclosure tied to ARCT-032, ARCT-810, and CSL Seqirus-partnered COVID-19 and flu programs
- Key milestones include planned EOP2 meeting, ARCT-032 Phase 2 study, and potential ARCT-810 pivotal or pediatric development
- Cash position, expected burn, and runway identified as material investor considerations
- Press release receives limited liability protection and is not incorporated into SEC filings absent specific reference
Item 5.02 · Departure/Election of Directors or Officers
- Dennis Mulroy appointed CFO effective May 1, 2026, becoming principal financial officer after the March 31, 2026 10-Q filing
- Experienced biotech finance executive, previously CFO at AnaptysBio and La Jolla Pharmaceutical
- Annual salary $520,000 with bonus opportunity up to 40% of base salary
- Equity award of 100,000 options vesting over four years, including 25% after one year
- Joe Roberts remains interim principal accounting officer and Controller, preserving accounting continuity
Item 7.01 · Regulation FD Disclosure
- Standard Regulation FD disclaimer covering the 8-K and press release
- Disclosure not deemed filed under Exchange Act Section 18 or incorporated into other SEC filings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcturus Therapeutics Holdings Inc. 8-K filings
Get the next ARCT 8-K as it lands
Follow ARCT for push alerts, or ask the research agent what this filing means.